基于降钙素原的急性胰腺炎抗生素使用算法(PROCAP):随机对照试验研究方案
PROCAP试验为单中心、随机、对照、单盲、双臂实用性临床与成本效果研究,拟纳入200例急性胰腺炎患者,1:1分配至PCT算法指导抗生素使用组或标准治疗组。主要结局为指数住院期间抗生素使用的二分类结局,以20%绝对变化为临床重要差异,检验PCT算法减少抗生素使用且不影响安全性。
要点
- PCT算法指导急性胰腺炎抗生素的启动、继续与停用,可能减少抗生素使用。
- 主要结局为指数住院期间是否使用抗生素,安全性终点为全因死亡非劣效。
- 计划纳入200例,每组97例可检测20%绝对差异(80%把握度,双侧5%显著性)。
核心结论
- PROCAP试验检验基于PCT的算法指导急性胰腺炎抗生素启动、继续和停用可减少抗生素使用且不增加不良结局的假设。
研究设计与样本
- 单中心、随机、对照、单盲、双臂实用性临床与成本效果试验,按1:1分配至干预组或标准治疗组。
- 计划招募200例临床诊断急性胰腺炎的患者,每组97例可检测20%绝对变化(80%把握度,双侧5%显著性)。
- 分析遵循意向性治疗原则。
关键数值与推荐
- 主要结局为指数住院期间抗生素使用的二分类结局。
- 次要结局包括全因死亡非劣效安全性终点、抗生素使用天数、临床感染、多重耐药菌新分离株、住院时长、发作相关死亡及原因、生活质量(EuroQol EQ-5D)和成本分析。
- 20%的抗生素使用绝对变化被视为临床重要差异。
临床怎么用
- 若验证有效,PCT算法可用于指导急性胰腺炎患者抗生素的启动、继续与停用决策以减少抗生素暴露。
局限性
- 原文未报告研究结果,无法评估PCT算法的实际效应。
- 单中心设计可能限制外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiating infection from inflammation in acute pancreatitis is difficult, leading to overuse of antibiotics. Procalcitonin (PCT) measurement is a means of distinguishing infection from inflammation as levels rise rapidly in response to a pro-inflammatory stimulus of bacterial origin and normally fall after successful treatment. Algorithms based on PCT measurement can differentiate bacterial sepsis from a systemic inflammatory response. The PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP) trial tests the hypothesis that a PCT-based algorithm to guide initiation, continuation and discontinuation of antibiotics will lead to reduced antibiotic use in patients with acute pancreatitis and without an adverse effect on outcome. METHODS: This is a single-centre, randomised, controlled, single-blind, two-arm pragmatic clinical and cost-effectiveness trial. Patients with a clinical diagnosis of acute pancreatitis will be allocated on a 1:1 basis to intervention or standard care. Intervention will involve the use of a PCT-based algorithm to guide antibiotic use. The primary outcome measure will be the binary outcome of antibiotic use during index admission. Secondary outcome measures include: safety non-inferiority endpoint all-cause mortality; days of antibiotic use; clinical infections; new isolates of multiresistant bacteria; duration of inpatient stay; episode-related mortality and cause; quality of life (EuroQol EQ-5D); and cost analysis. A 20% absolute change in antibiotic use would be a clinically important difference. A study with 80% power and 5% significance (two-sided) would require 97 patients in each arm (194 patients in total): the study will aim to recruit 200 patients. Analysis will follow intention-to-treat principles. DISCUSSION: When complete, PROCAP will be the largest randomised trial of the use of a PCT algorithm to guide initiation, continuation and cessation of antibiotics in acute pancreatitis. PROCAP is the only randomised trial to date to compare standard care of acute pancreatitis as defined by the International Association of Pancreatology/American Pancreatic Association guidelines to patients having standard care but with all antibiotic prescribing decisions based on PCT measurement. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number, ISRCTN50584992. Registered on 7 February 2018.
引用
- Siriwardena AK, Jegatheeswaran S, Mason JM, et al. PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP): study protocol for a randomised controlled trial. Trials. 2019. PMID: 31358032. doi:10.1186/s13063-019-3549-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。